---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-042926"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:34:25.663448+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmuCell Q1 2024: Record sales $7.3M (+111% YoY); net loss narrows; FDA delays Re-Tain

## Summary
- Product sales of $7.3M, up 111% YoY from $3.4M; all-time quarterly record.
- Net loss improved to $438k ($0.06/sh) vs $2.3M loss ($0.30/sh) a year ago.
- Gross margin rose to 32% from 9%, driven by recovery from 2023 contamination events.
- Production output annualized to $28.7M (~96% of $30M capacity); backlog $9.1M.
- FDA issued Incomplete Letter for Re-Tain CMC; requires contract manufacturer inspection resolution before resubmission.

## SEC filing metadata
- accession: 0001213900-24-042926
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390024042926/0001213900-24-042926-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390024042926/ea0206072-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-042926
- JSON: https://secwatch.observer/filing/0001213900-24-042926.json
- Plain text: https://secwatch.observer/filing/0001213900-24-042926.txt

## Key facts
- Earnings Releases
  IMMUCELL CORP /DE/ reported the quarter ended March 31, 2024 results: revenue $7.3 million, net income Net loss was $438,000, EPS $0.06 per basic share.
  - Period: the quarter ended March 31, 2024
  - Revenue: $7.3 million
  - Net income: Net loss was $438,000
  - EPS: $0.06 per basic share
  - Result: reported results
  source text: comparable period ended March 31, 2023. Total sales during the trailing twelve-month period ended March 31, 2024 were 33% above the comparable period ended March 31, 2023. The $7.3 million in sales recorded during the first quarter of 2024 represents an all-time quarterly sales record for the Company. The next highest quarter was $6 million recorded during the
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390024042926/0001213900-24-042926-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.